Fiona E. McCann

Fiona E. McCann

Auto-generated profile, based on publicly available information

Fiona E. McCann

Kennedy Institute of Rheumatology, Old Road Campus, University of Oxford, Oxford, United Kingdom

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Cell
Verified
Journal Article
Closed access
MSMajid Shayeghi
Majid Shayeghi
GLGladys O. Latunde-Dada
Gladys O. Latunde-Dada
JOJonathan S. Oakhill
Jonathan S. Oakhill
ALAbas H. Laftah
Abas H. Laftah
KTKen Takeuchi
Ken Takeuchi
AMAndrew T. McKie
Andrew T. McKie

4 May 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KBKatrina Blazek
Katrina Blazek
HEHayley L. Eames
Hayley L. Eames
MWMiriam Weiss
Miriam Weiss
ABAdam J. Byrne
Adam J. Byrne
DPDany Perocheau
Dany Perocheau
IUIrina A. Udalova
Irina A. Udalova
The most studied biological role of type III interferons (IFNs) has so far been their antiviral activity, but their role in autoimmune and inflammatory diseases remains largely unexplored. Here, we show that treatment with IFN-λ2/IL-28A completely halts and reverses the development of collagen-induced arthritis (CIA) and discover cellular and molecular mechanisms of IL-28A antiinflammatory function. We demonstrate that treatment with IL-28A dramatically reduces numbers of proinflammatory IL-17–producing Th17 and γδ T cells in the joints and inguinal lymph nodes, without affecting T cell proliferative responses or levels of anticollagen antibodies. IL-28A exerts its antiinflammatory effect by restricting recruitment of IL-1b–expressing neutrophils, which are important for amplification of inflammation. We identify neutrophils as cells expressing high levels of IFN-λ receptor 1 (IFNLR1)–IL-28 receptor α (IL28RA) and targeted by IL-28A. Our data highlight neutrophils as contributors to the pathogenesis of autoimmune arthritis and present IFN-λs or agonists of IFNLR1–IL28RA as putative new therapeutics for neutrophil-driven inflammation.

28 June 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe ULTRA-DD Consortium
The ULTRA-DD Consortium
HFHai Fang
Hai Fang
HWHans De Wolf
Hans De Wolf
BKBogdan Knezevic
Bogdan Knezevic
KBKatie L. Burnham
Katie L. Burnham
JKJulian C. Knight
Julian C. Knight
Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide association studies for drug target discovery in complex diseases remains challenging4,5,6. Here, we show that integration of functional genomic and immune-related annotations, together with knowledge of network connectivity, maximizes the informativeness of genetics for target validation, defining the target prioritization landscape for 30 immune traits at the gene and pathway level. We demonstrate how our genetics-led drug target prioritization approach (the priority index) successfully identifies current therapeutics, predicts activity in high-throughput cellular screens (including L1000, CRISPR, mutagenesis and patient-derived cell assays), enables prioritization of under-explored targets and allows for determination of target-level trait relationships. The priority index is an open-access, scalable system accelerating early-stage drug target selection for immune-mediated disease.

20 October 2008 in Journal of Experimental Medicine
Verified
Journal Article
Open access
CNClare A. Notley
Clare A. Notley
JIJulia J. Inglis
Julia J. Inglis
SASaba Alzabin
Saba Alzabin
FMFiona E. McCann
Fiona E. McCann
KMKay E. McNamee
Kay E. McNamee
RWRichard O. Williams
Richard O. Williams
IL-17 is implicated in the pathogenesis of rheumatoid arthritis (RA) and has previously been shown to be induced by tumor necrosis factor (TNF) in vitro. The aim of this study was to assess the impact of TNF inhibition on IL-17 production in collagen-induced arthritis, a model of RA. TNF blockade using TNFR-Fc fusion protein or anti-TNF monoclonal antibody reduced arthritis severity but, unexpectedly, expanded populations of Th1 and Th17 cells, which were shown by adoptive transfer to be pathogenic. Th1 and Th17 cell populations were also expanded in collagen-immunized TNFR p55−/− but not p75−/− mice. The expression of IL-12/IL-23 p40 was up-regulated in lymph nodes (LN) from p55−/− mice, and the expansion of Th1/Th17 cells was abrogated by blockade of p40. Treatment of macrophages with rTNF also inhibited p40 production in vitro. These findings indicate that at least one of the ways in which TNF regulates Th1/Th17 responses in arthritis is by down-regulating the expression of p40. Finally, although TNF blockade increased numbers of Th1 and Th17 cells in LN, it inhibited their accumulation in the joint, thereby providing an explanation for the paradox that anti-TNF therapy ameliorates arthritis despite increasing numbers of pathogenic T cells.

20 March 2008 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
JIJulia J Inglis
Julia J Inglis
EŠEgle Šimelyte
Egle Šimelyte
FMFiona E McCann
Fiona E McCann
GCGabriel Criado
Gabriel Criado
RWRichard O Williams
Richard O Williams

19 November 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
LCLeo M. Carlin
Leo M. Carlin
KEKonstantina Eleme
Konstantina Eleme
FMFiona E. McCann
Fiona E. McCann
DDDaniel M. Davis
Daniel M. Davis
After accumulation of target cell human leukocyte antigen (HLA)-C at inhibitory natural killer (NK) cell immune synapses, some HLA-C transfers from target cells to NK cell plasma membranes and cytoplasm. This unexpected intercellular transfer of HLA-C is dependent on NK receptor recognition, since HLA-Cw6 or -Cw4 but not -Cw3 transfer to an NK transfectant expressing killer Ig-like receptor (KIR)2DL1. Strikingly, live-cell time-lapse laser scanning confocal microscopy shows vesicles containing target cell green fluorescent protein–tagged HLA-C migrating away from immune synapses into NK cells. Unlike clustering of HLA-C at the immune synapse, intercellular transfer of HLA-C is dependent on NK cell ATP, but not target cell ATP. However, the intercellular transfer of HLA-C is not dependent on active polymerization of the actin cytoskeleton. In addition, different arrangements of HLA-C are seen at inhibitory NK immune synapses, and these alter as NK synapses mature, but in a fashion distinct from that seen upon T cell activation.